Diagnosis and Management of Splenic Amoebiasis

Epidemiology & Clinical Presentation

Clinical splenomegaly is observed in only about 30 % of patients with splenic amoebiasis, making it an unreliable diagnostic sign. 1
A prior episode of dysentery is reported by roughly 20 % of patients, and concurrent diarrhea is present in only ≈10 % at the time of presentation. 2
Persistent or recurrent fever despite initial antimicrobial therapy should raise suspicion for splenic involvement. 2

Contrast‑enhanced CT is the gold‑standard imaging modality, demonstrating 90–95 % sensitivity and specificity for detecting splenic abscesses as contrast‑enhancing cystic lesions. 3
MRI provides equivalent diagnostic accuracy (90–95 % sensitivity/specificity) and can differentiate amoebic abscesses from bland infarcts. 1
Ultrasound is less sensitive; abscesses appear as sonolucent lesions. 3
Amoebic serology (indirect haemagglutination) has >90 % sensitivity for identifying amoebic abscesses. 2
Typical laboratory findings include neutrophil leukocytosis (>10 × 10⁹ /L), elevated inflammatory markers, and raised alkaline phosphatase. 2
Faecal microscopy is usually negative in splenic amoebiasis and therefore not a reliable diagnostic test. 2

Empiric metronidazole 500 mg orally three times daily for 7–10 days achieves >90 % cure rates in amoebic abscesses. 2
Tinidazole 2 g daily for 3 days is an effective alternative with a lower incidence of nausea. 2
When a pyogenic abscess cannot be excluded, broad‑spectrum antibiotics (e.g., ceftriaxone plus metronidazole) should be added until a definitive diagnosis is confirmed. 2
The majority of patients show clinical improvement within 72–96 hours after initiating therapy. 2
After completing metronidazole or tinidazole, luminal amoebicide therapy (e.g., diloxanide furoate 500 mg three times daily or paromomycin 30 mg/kg/day) is required to reduce relapse risk, even if stool microscopy is negative. 2

Splenic amoebic abscesses have higher failure rates with medical therapy alone and more often require procedural intervention compared with hepatic amoebic abscesses. 4
Percutaneous aspiration is recommended when there is diagnostic uncertainty between amoebic and pyogenic abscesses. 2
Needle aspiration should be considered if symptoms persist after 4 days of appropriate medical treatment. 2
Splenectomy is the preferred definitive treatment; percutaneous drainage in this setting shows failure rates ranging from 14 % to 75 %. 1
Surgical drainage is indicated for cases of failed medical management or when there is an imminent risk of splenic rupture. 2

Lifelong vaccination (pneumococcal, meningococcal, and Haemophilus influenzae type B) and antibiotic prophylaxis are required to prevent overwhelming post‑splenectomy infection (OPSI). 1
Prophylactic antibiotics should be prescribed indefinitely. 1

Do not rely on the presence of clinical splenomegaly as an indicator of disease severity or presence. 1
Omitting luminal amoebicide therapy after metronidazole or tinidazole markedly increases the risk of relapse. 2

For patients with a single, accessible splenic abscess, percutaneous catheter drainage is recommended as the first‑line intervention when a safe percutaneous window is available. 5
Criteria for drain removal after successful PCD include: resolution of infection signs, catheter output < 10–20 mL, and radiologic confirmation of abscess resolution on repeat imaging. 5

In the presence of multiple, non‑communicating, or complex splenic abscesses, immediate splenectomy is advised because percutaneous drainage has a high failure rate ranging from 14.3 % to 75 %. 5
Absolute indications for splenectomy:
Attempting percutaneous drainage for multiple splenic abscesses is discouraged due to failure rates up to 75 %, making splenectomy the preferred definitive treatment. 5